Literature DB >> 25209843

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.

Peter Valent1, Jörg Berger, Sabine Cerny-Reiterer, Barbara Peter, Gregor Eisenwort, Gregor Hoermann, Leonhard Müllauer, Christine Mannhalter, Michael Steurer, Peter Bettelheim, Hans-Peter Horny, Michel Arock.   

Abstract

Mast cell leukemia (MCL) is a rare, life-threatening malignancy defined by a substantial increase in neoplastic mast cells (MCs) in bone marrow (BM) smears, drug-resistance, and a poor prognosis. In most patients, the survival time is less than 1 year. However, exceptional cases may present with a less malignant course. We report on a 49-year-old female patient with MCL diagnosed in 2013. In February 2013, first symptoms, including flushing, headache, and diarrhea, were recorded. In addition, mild anemia was detected. The disease was characterized by a massive increase in well-granulated, mature, and often spindle-shaped MCs (80 %) in BM smears. The serum tryptase level amounted to 332 ng/mL. Like in most other MCL patients, no skin lesions were detected. However, unlike in other patients, tryptase levels remained stable, and no other signs or symptoms of MCL-induced organ damage were found. Sequencing studies revealed an isolated S476I point mutation in KIT but no mutation in codon 816. The patient received histamine receptor blockers but refused cytoreductive therapy. After 9 months, still no progression or organ damage was detected. However, progression with transformation to acute MCL occurred after 12 months. We propose that the chronic type of MCL with stable conditions, absence of organ damage, and a mature MC morphology is recognized as a distinct entity that should be distinguished from the acute variant of MCL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25209843      PMCID: PMC4896380          DOI: 10.1007/s00277-014-2207-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  40 in total

1.  Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.

Authors:  Karl Sotlar; Sabine Cerny-Reiterer; Karina Petat-Dutter; Harald Hessel; Sabina Berezowska; Leonhard Müllauer; Peter Valent; Hans-Peter Horny
Journal:  Mod Pathol       Date:  2010-12-24       Impact factor: 7.842

2.  Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.

Authors:  Ken H Lim; Animesh Pardanani; Joseph H Butterfield; Chin-Yang Li; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2009-12       Impact factor: 10.047

Review 3.  Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Authors:  P Valent; H P Horny; L Escribano; B J Longley; C Y Li; L B Schwartz; G Marone; R Nuñez; C Akin; K Sotlar; W R Sperr; K Wolff; R D Brunning; R M Parwaresch; K F Austen; K Lennert; D D Metcalfe; J W Vardiman; J M Bennett
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

Review 4.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

Authors:  H P Horny; P Valent
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

5.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

Authors:  Jason Gotlib; Caroline Berubé; Joseph D Growney; Ching-Cheng Chen; Tracy I George; Christopher Williams; Tomohiro Kajiguchi; Jia Ruan; Stan L Lilleberg; Jeffrey A Durocher; Jack H Lichy; Yanfeng Wang; Pamela S Cohen; Daniel A Arber; Michael C Heinrich; Len Neckers; Stephen J Galli; D Gary Gilliland; Steven E Coutré
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

6.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.

Authors:  Animesh Pardanani; Ken-Hong Lim; Terra L Lasho; Christy Finke; Rebecca F McClure; Chin-Yang Li; Ayalew Tefferi
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

7.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

Authors:  B J Longley; L Tyrrell; S Z Lu; Y S Ma; K Langley; T G Ding; T Duffy; P Jacobs; L H Tang; I Modlin
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

Review 8.  Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.

Authors:  P Valent; C Akin; L Escribano; M Födinger; K Hartmann; K Brockow; M Castells; W R Sperr; H C Kluin-Nelemans; N A T Hamdy; O Lortholary; J Robyn; J van Doormaal; K Sotlar; A W Hauswirth; M Arock; O Hermine; A Hellmann; M Triggiani; M Niedoszytko; L B Schwartz; A Orfao; H-P Horny; D D Metcalfe
Journal:  Eur J Clin Invest       Date:  2007-06       Impact factor: 4.686

9.  FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H.

Authors:  Peter Valent; Katharina Blatt; Gregor Eisenwort; Harald Herrmann; Sabine Cerny-Reiterer; Renate Thalhammer; Leonhard Müllauer; Gregor Hoermann; Irina Sadovnik; Ilse Schwarzinger; Wolfgang R Sperr; Christine Mannhalter; Hans-Peter Horny
Journal:  Leuk Res Rep       Date:  2013-11-26

10.  ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.

Authors:  Gandhi Damaj; Magalie Joris; Olivia Chandesris; Katia Hanssens; Erinn Soucie; Danielle Canioni; Brigitte Kolb; Isabelle Durieu; Emanuel Gyan; Cristina Livideanu; Stephane Chèze; Momar Diouf; Reda Garidi; Sophie Georgin-Lavialle; Vahid Asnafi; Ludovic Lhermitte; Christian Lavigne; David Launay; Michel Arock; Olivier Lortholary; Patrice Dubreuil; Olivier Hermine
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more
  5 in total

1.  Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

Authors:  D J DeAngelo; T I George; A Linder; C Langford; C Perkins; J Ma; P Westervelt; J D Merker; C Berube; S Coutre; M Liedtke; B Medeiros; D Sternberg; C Dutreix; P-A Ruffie; C Corless; T J Graubert; J Gotlib
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

Review 2.  Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.

Authors:  Oscar González-López; Javier I Muñoz-González; Alberto Orfao; Iván Álvarez-Twose; Andrés C García-Montero
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

3.  A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data.

Authors:  Jeonghwan Youk; Youngil Koh; Ji-Won Kim; Dae-Yoon Kim; Hyunkyung Park; Woo June Jung; Kwang-Sung Ahn; Hongseok Yun; Inho Park; Choong-Hyun Sun; Seungmook Lee; Sung-Soo Yoon
Journal:  Blood Res       Date:  2016-03-25

4.  The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.

Authors:  Mohamad Jawhar; Juliana Schwaab; Manja Meggendorfer; Nicole Naumann; Hans-Peter Horny; Karl Sotlar; Torsten Haferlach; Karla Schmitt; Alice Fabarius; Peter Valent; Wolf-Karsten Hofmann; Nicholas C P Cross; Georgia Metzgeroth; Andreas Reiter
Journal:  Haematologica       Date:  2017-03-02       Impact factor: 9.941

Review 5.  Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.

Authors:  Siba El Hussein; Helen T Chifotides; Joseph D Khoury; Srdan Verstovsek; Beenu Thakral
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.